ESC 25: Heart Failure Highlights

57 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.

Trials covered in detail include:
REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction
BETAMI-DANBLOCK: Beta-Blockers after Myocardial Infarction in Patients without Heart Failure
DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
AQUATIC: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

Recorded remotely from Los Angeles, 2025.
Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Categoria
Cardiology
Commenta per primo questo video.

Prossimo